53 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Here's Why You Should Retain Walgreens Boots (WBA) For Now https://www.zacks.com/stock/news/2237551/here-s-why-you-should-retain-walgreens-boots-wba-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2237551 Mar 07, 2024 - Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.
Abbott (ABT) to Reduce Childhood Malnutrition With New Pact https://www.zacks.com/stock/news/2237550/abbott-abt-to-reduce-childhood-malnutrition-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2237550 Mar 07, 2024 - Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales https://www.zacks.com/stock/news/2237419/phibro-pahc-appears-well-poised-on-launches-vaccine-sales?cid=CS-ZC-FT-analyst_blog|zer_report_update-2237419 Mar 07, 2024 - Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
Reasons to Retain Prestige Consumer (PBH) Stock for Now https://www.zacks.com/stock/news/2236222/reasons-to-retain-prestige-consumer-pbh-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2236222 Mar 05, 2024 - Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.
CVS Health (CVS) Expands In-Home Diagnostic Care With New Test https://www.zacks.com/stock/news/2236218/cvs-health-cvs-expands-in-home-diagnostic-care-with-new-test?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236218 Mar 05, 2024 - CVS Health's (CVS) new launch will enable early detection of heart arrhythmia and can help mitigate symptoms and more severe complications.
Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact https://www.zacks.com/stock/news/2234635/myriad-genetics-mygn-to-evaluate-mrd-testing-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2234635 Mar 01, 2024 - Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.
Here's Why Investors Should Retain STERIS (STE) Stock for Now https://www.zacks.com/stock/news/2232656/here-s-why-investors-should-retain-steris-ste-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2232656 Feb 27, 2024 - Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.
Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity https://www.zacks.com/stock/news/2232652/quest-diagnostics-dgx-new-pact-to-reduce-food-insecurity?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2232652 Feb 27, 2024 - Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.
HAE or SYK: Which Is the Better Value Stock Right Now? https://www.zacks.com/stock/news/2232605/hae-or-syk-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2232605 Feb 27, 2024 - HAE vs. SYK: Which Stock Is the Better Value Option?
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now https://www.zacks.com/stock/news/2231893/here-s-why-you-should-buy-edward-lifesciences-ew-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2231893 Feb 26, 2024 - Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

Pages: 123456

<<<Page 3>